Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Genetic modulation of tau phosphorylation in the mouse.

Brich J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, Jin LW, Mumby M, Churchill G, Herz J, Cooper JA.

J Neurosci. 2003 Jan 1;23(1):187-92.

2.

Identification of Stk25 as a genetic modifier of Tau phosphorylation in Dab1-mutant mice.

Matsuki T, Zaka M, Guerreiro R, van der Brug MP, Cooper JA, Cookson MR, Hardy JA, Howell BW.

PLoS One. 2012;7(2):e31152. doi: 10.1371/journal.pone.0031152. Epub 2012 Feb 15.

3.

Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1.

Boutajangout A, Authelet M, Blanchard V, Touchet N, Tremp G, Pradier L, Brion JP.

Neurobiol Dis. 2004 Feb;15(1):47-60.

PMID:
14751770
4.

Effect of cortistatin on tau phosphorylation at Ser262 site.

Rubio A, Pérez M, de Lecea L, Avila J.

J Neurosci Res. 2008 Aug 15;86(11):2462-75. doi: 10.1002/jnr.21689.

PMID:
18438934
5.

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.

J Pharmacol Exp Ther. 2007 Nov;323(2):438-49. Epub 2007 Aug 24.

8.

Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease.

Asuni AA, Perry VH, O'Connor V.

Biochem Soc Trans. 2010 Apr;38(2):545-51. doi: 10.1042/BST0380545. Review.

PMID:
20298219
9.

Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.

Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, Ramakers GJ, de Vos K, Krugers H, Tomiyama T, Mori H, Joels M, van Leuven F, Lucassen PJ.

J Neurosci. 2006 Mar 29;26(13):3514-23.

10.

DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.

Ryoo SR, Jeong HK, Radnaabazar C, Yoo JJ, Cho HJ, Lee HW, Kim IS, Cheon YH, Ahn YS, Chung SH, Song WJ.

J Biol Chem. 2007 Nov 30;282(48):34850-7. Epub 2007 Sep 28.

11.
12.
13.

Phosphorylation state of tau in the hippocampus of apolipoprotein E4 and E3 knock-in mice.

Kobayashi M, Ishiguro K, Katoh-Fukui Y, Yokoyama M, Fujita SC.

Neuroreport. 2003 Apr 15;14(5):699-702.

PMID:
12692466
14.

Regulation of protein tyrosine kinase signaling by substrate degradation during brain development.

Arnaud L, Ballif BA, Cooper JA.

Mol Cell Biol. 2003 Dec;23(24):9293-302.

15.
16.

Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.

Ferrer I, Barrachina M, Puig B, Martínez de Lagrán M, Martí E, Avila J, Dierssen M.

Neurobiol Dis. 2005 Nov;20(2):392-400.

PMID:
16242644
17.

Substrate-specific reduction of PP2A activity exaggerates tau pathology.

Deters N, Ittner LM, Götz J.

Biochem Biophys Res Commun. 2009 Feb 6;379(2):400-5. doi: 10.1016/j.bbrc.2008.12.140. Epub 2009 Jan 4.

PMID:
19126401
18.

Impaired glutamate transport in a mouse model of tau pathology in astrocytes.

Dabir DV, Robinson MB, Swanson E, Zhang B, Trojanowski JQ, Lee VM, Forman MS.

J Neurosci. 2006 Jan 11;26(2):644-54.

19.

The role of tau phosphorylation in the pathogenesis of Alzheimer's disease.

Mi K, Johnson GV.

Curr Alzheimer Res. 2006 Dec;3(5):449-63. Review.

PMID:
17168644
20.

Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade.

Ohkubo N, Lee YD, Morishima A, Terashima T, Kikkawa S, Tohyama M, Sakanaka M, Tanaka J, Maeda N, Vitek MP, Mitsuda N.

FASEB J. 2003 Feb;17(2):295-7. Epub 2002 Dec 18.

PMID:
12490540

Supplemental Content

Support Center